Docetaxel-titanate nanotubes enhance radiosensitivity in an androgen-independent prostate cancer model

Céline Mirjolet,1 Julien Boudon,2 Alexis Loiseau,2 Sandy Chevrier,1 Romain Boidot,1 Alexandra Oudot,3 Bertrand Collin,3 Etienne Martin,1 Pattayil Alias Joy,4 Nadine Millot,2 Gilles Créhange1 1Department of Radiation Oncology, Center Georges-François Leclerc, Dijon,...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	C Mirjolet, Boudon J, Loiseau A, Chevrier S, Boidot R, Oudot A, Collin B, Martin E, Joy PA, Millot N, Créhange G
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	prostate cancer docetaxel nanocarrier titanate nanotubes radiosensitivity Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/9a843c50a031463baaa0fce8e3eeea19
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9a843c50a031463baaa0fce8e3eeea19
record_format	dspace
spelling	oai:doaj.org-article:9a843c50a031463baaa0fce8e3eeea192021-12-02T01:32:31ZDocetaxel-titanate nanotubes enhance radiosensitivity in an androgen-independent prostate cancer model1178-2013https://doaj.org/article/9a843c50a031463baaa0fce8e3eeea192017-08-01T00:00:00Zhttps://www.dovepress.com/docetaxel-titanate-nanotubes-enhance-radiosensitivity-in-an-androgen-i-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Céline Mirjolet,1 Julien Boudon,2 Alexis Loiseau,2 Sandy Chevrier,1 Romain Boidot,1 Alexandra Oudot,3 Bertrand Collin,3 Etienne Martin,1 Pattayil Alias Joy,4 Nadine Millot,2 Gilles Créhange1 1Department of Radiation Oncology, Center Georges-François Leclerc, Dijon, France; 2Laboratoire Interdisciplinaire Carnot de Bourgogne, Dijon, France; 3Preclinical Imaging Platform, Nuclear Medicine Department, Center Georges-François Leclerc, Dijon, France; 4CSIR-National Chemical Laboratory (CSIR-NCL), Pune, India Abstract: Around 40% of high-risk prostate cancer patients who undergo radiotherapy (RT) will experience biochemical failure. Chemotherapy, such as docetaxel (DTX), can enhance the efficacy of RT. Multidrug resistance mechanisms often limit drug efficacy by decreasing intracellular concentrations of drugs in tumor cells. It is, therefore, of interest to develop nanocarriers of DTX to maintain the drug inside cancer cells and thus improve treatment efficacy. The purpose of this study was to investigate the use of titanate nanotubes (TiONts) to develop a TiONts-DTX nanocarrier and to evaluate its radiosensitizing in vivo efficacy in a prostate cancer model. In vitro cytotoxic activity of TiONts-DTX was evaluated using an MTS assay. The biodistribution of TiONts-DTX was analyzed in vivo by single-photon emission computed tomography. The benefit of TiONts-DTX associated with RT was evaluated in vivo. Eight groups with seven mice in each were used to evaluate the efficacy of the nanohybrid combined with RT: control with buffer IT injection ± RT, free DXL ± RT, TiONts ± RT and TiONts-DXL ± RT. Mouse behavior, health status and tumor volume were monitored twice a week until the tumor volume reached a maximum of 2,000 mm3. More than 70% of nanohybrids were localized inside the tumor 96 h after administration. Tumor growth was significantly slowed by TiONts-DTX associated with RT, compared with free DTX in the same conditions (P=0.013). These results suggest that TiONts-DTX improved RT efficacy and might enhance local control in high-risk localized prostate cancer. Keywords: prostate cancer, docetaxel nanocarrier, titanate nanotubes, radiosensitivity, nanoparticleC MirjoletBoudon JLoiseau AChevrier SBoidot ROudot ACollin BMartin EJoy PAMillot NCréhange GDove Medical Pressarticleprostate cancerdocetaxel nanocarriertitanate nanotubesradiosensitivityMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 12, Pp 6357-6364 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	prostate cancer docetaxel nanocarrier titanate nanotubes radiosensitivity Medicine (General) R5-920
spellingShingle	prostate cancer docetaxel nanocarrier titanate nanotubes radiosensitivity Medicine (General) R5-920 C Mirjolet Boudon J Loiseau A Chevrier S Boidot R Oudot A Collin B Martin E Joy PA Millot N Créhange G Docetaxel-titanate nanotubes enhance radiosensitivity in an androgen-independent prostate cancer model
description	Céline Mirjolet,1 Julien Boudon,2 Alexis Loiseau,2 Sandy Chevrier,1 Romain Boidot,1 Alexandra Oudot,3 Bertrand Collin,3 Etienne Martin,1 Pattayil Alias Joy,4 Nadine Millot,2 Gilles Créhange1 1Department of Radiation Oncology, Center Georges-François Leclerc, Dijon, France; 2Laboratoire Interdisciplinaire Carnot de Bourgogne, Dijon, France; 3Preclinical Imaging Platform, Nuclear Medicine Department, Center Georges-François Leclerc, Dijon, France; 4CSIR-National Chemical Laboratory (CSIR-NCL), Pune, India Abstract: Around 40% of high-risk prostate cancer patients who undergo radiotherapy (RT) will experience biochemical failure. Chemotherapy, such as docetaxel (DTX), can enhance the efficacy of RT. Multidrug resistance mechanisms often limit drug efficacy by decreasing intracellular concentrations of drugs in tumor cells. It is, therefore, of interest to develop nanocarriers of DTX to maintain the drug inside cancer cells and thus improve treatment efficacy. The purpose of this study was to investigate the use of titanate nanotubes (TiONts) to develop a TiONts-DTX nanocarrier and to evaluate its radiosensitizing in vivo efficacy in a prostate cancer model. In vitro cytotoxic activity of TiONts-DTX was evaluated using an MTS assay. The biodistribution of TiONts-DTX was analyzed in vivo by single-photon emission computed tomography. The benefit of TiONts-DTX associated with RT was evaluated in vivo. Eight groups with seven mice in each were used to evaluate the efficacy of the nanohybrid combined with RT: control with buffer IT injection ± RT, free DXL ± RT, TiONts ± RT and TiONts-DXL ± RT. Mouse behavior, health status and tumor volume were monitored twice a week until the tumor volume reached a maximum of 2,000 mm3. More than 70% of nanohybrids were localized inside the tumor 96 h after administration. Tumor growth was significantly slowed by TiONts-DTX associated with RT, compared with free DTX in the same conditions (P=0.013). These results suggest that TiONts-DTX improved RT efficacy and might enhance local control in high-risk localized prostate cancer. Keywords: prostate cancer, docetaxel nanocarrier, titanate nanotubes, radiosensitivity, nanoparticle
format	article
author	C Mirjolet Boudon J Loiseau A Chevrier S Boidot R Oudot A Collin B Martin E Joy PA Millot N Créhange G
author_facet	C Mirjolet Boudon J Loiseau A Chevrier S Boidot R Oudot A Collin B Martin E Joy PA Millot N Créhange G
author_sort	C Mirjolet
title	Docetaxel-titanate nanotubes enhance radiosensitivity in an androgen-independent prostate cancer model
title_short	Docetaxel-titanate nanotubes enhance radiosensitivity in an androgen-independent prostate cancer model
title_full	Docetaxel-titanate nanotubes enhance radiosensitivity in an androgen-independent prostate cancer model
title_fullStr	Docetaxel-titanate nanotubes enhance radiosensitivity in an androgen-independent prostate cancer model
title_full_unstemmed	Docetaxel-titanate nanotubes enhance radiosensitivity in an androgen-independent prostate cancer model
title_sort	docetaxel-titanate nanotubes enhance radiosensitivity in an androgen-independent prostate cancer model
publisher	Dove Medical Press
publishDate	2017
url	https://doaj.org/article/9a843c50a031463baaa0fce8e3eeea19
work_keys_str_mv	AT cmirjolet docetaxeltitanatenanotubesenhanceradiosensitivityinanandrogenindependentprostatecancermodel AT boudonj docetaxeltitanatenanotubesenhanceradiosensitivityinanandrogenindependentprostatecancermodel AT loiseaua docetaxeltitanatenanotubesenhanceradiosensitivityinanandrogenindependentprostatecancermodel AT chevriers docetaxeltitanatenanotubesenhanceradiosensitivityinanandrogenindependentprostatecancermodel AT boidotr docetaxeltitanatenanotubesenhanceradiosensitivityinanandrogenindependentprostatecancermodel AT oudota docetaxeltitanatenanotubesenhanceradiosensitivityinanandrogenindependentprostatecancermodel AT collinb docetaxeltitanatenanotubesenhanceradiosensitivityinanandrogenindependentprostatecancermodel AT martine docetaxeltitanatenanotubesenhanceradiosensitivityinanandrogenindependentprostatecancermodel AT joypa docetaxeltitanatenanotubesenhanceradiosensitivityinanandrogenindependentprostatecancermodel AT millotn docetaxeltitanatenanotubesenhanceradiosensitivityinanandrogenindependentprostatecancermodel AT crehangeg docetaxeltitanatenanotubesenhanceradiosensitivityinanandrogenindependentprostatecancermodel
_version_	1718403029738192896

Docetaxel-titanate nanotubes enhance radiosensitivity in an androgen-independent prostate cancer model

Ejemplares similares